CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 20 enrolled
Drug / intervention
Lully Sleep Guardian +1 moredevice
Likely dose
Not stated in record
Key inclusion· 3
  • Diagnosis of benign nocturnal enuresis
  • Age 5-17 years
  • Must have or have access to an Apple iPhone, iPad, or iPod Touch
Key exclusion· 10
  • Diurnal enuresis (daytime wetting)
  • Neurogenic bladder
  • Cerebral palsy
  • Epilepsy or seizure history

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03047720
NCT03047720N/ACompleted

Scheduled Awakenings for the Treatment of Nocturnal Enuresis

Indiana University·interventional·Posted Feb 9, 2017·Updated Nov 17, 2020

In Brief

A clinical study evaluating Lully Sleep Guardian for Nocturnal Enuresis. Completed, enrolled 20 participants across 1 site.

Detailed Summary

This study is a simple effectiveness trial to determine if the Lully Sleep Guardian has any effect on benign nocturnal enuresis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedFeb 9, 2017
Enrollment StartNov 4, 2016
Primary CompletionAug 7, 2018
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 9.4 years ago

Interventions

Lully Sleep Guardiandevice

In the initial phase, participant baseline is established. In the Therapeutic Phase, each participant will complete the study phases (S1 and S2) in the order determined by their assigned treatment arm. During the scheduled awakening protocol using Lully Sleep Guardian, a scheduled awakening will be performed each night with the Lully pod. During the initial and therapeutic phases of this study, participants are asked to enter responses daily into a Lully Study app. The app will send a prompt each morning. The questions the participant is prompted to answer serve to document occurrence of bedwetting and the degree of wetness. In addition, the family will complete the KIDSCREEN 27 and the Vancouver questionnaire at defined intervals throughout the study.

Lully Sleep Guardiandevice

In the initial phase, participant baseline is established. In the Therapeutic Phase, each participant will complete the study phases (S1 and S2) in the order determined by their assigned treatment arm. During the scheduled awakening protocol using Lully Sleep Guardian, a scheduled awakening will be performed each night with the Lully pod. During the initial and therapeutic phases of this study, participants are asked to enter responses daily into a Lully Study app. The app will send a prompt each morning. The questions the participant is prompted to answer serve to document occurrence of bedwetting and the degree of wetness. In addition, the family will complete the KIDSCREEN 27 and the Vancouver questionnaire at defined intervals throughout the study.